{"schema_version":"1.0","type":"article","title":"超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！","url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.md","lang":"zh-Hant","date":"2026-08-04","publish_at":"2026-08-04T08:00:00+08:00","updated_at":"2026-08-04","category":"商業分析系列","topic":"商業分析系列","tags":["AstraZeneca","阿斯特捷利康","Bristol Myers Squibb","BMS","百時美施貴寶","生技併購","大藥廠","專利懸崖","腫瘤新藥","ADC","CAR-T","反壟斷"],"summary":"Financial Times 報導 AstraZeneca 與 BMS 曾探討結合，合計市值接近 4,000 億美元。這不是已簽交易；真正的產業問題是 2030 成長、Eliquis／Opdivo 獨占期、腫瘤管線重疊、反壟斷與整合能否買到時間。","key_points":[],"facts":[],"sections":["01｜為什麼可能是現在？","02｜合併後，會是一張多誇張的腫瘤地圖？","03｜肝癌與 CAR-T，已經看得到正面重疊","04｜現在走到哪一步？報導是真的，交易還沒成立","05｜就算談成，還要過反壟斷這一關","06｜台灣有真實角色，但不是亂貼概念股","結語｜4,000 億美元，買得到規模，買得到時間嗎？","參考資料","免責聲明"],"references":[{"title":"[Financial Times","source":"AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up]","date":"","url":"https://www.ft.com/content/e9027253-e13c-460a-a4b1-f9047e5a6ca7"},{"title":"[Reuters","source":"AstraZeneca shares fall on Bristol Myers Squibb merger talks]","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-shares-fall-bristol-myers-squibb-merger-talks-2026-08-03/"},{"title":"[AstraZeneca","source":"2025 Form 20-F]","date":"","url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm"},{"title":"[AstraZeneca","source":"2030 年 800 億美元營收目標]","date":"","url":"https://news.cision.com/astrazeneca/r/astrazeneca-to-deliver--80bn-revenue-by-2030%2Cc3984754"},{"title":"[Bristol Myers Squibb","source":"2025 Form 10-K]","date":"","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm"},{"title":"[Bristol Myers Squibb","source":"2026 年第二季財報]","date":"","url":"https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspx"},{"title":"[FTC","source":"BMS／Celgene 最終命令]","date":"","url":"https://www.ftc.gov/news-events/news/press-releases/2020/01/ftc-approves-final-order-requiring-bristol-myers-squibb-company-celgene-corporation-divest-psoriasis"},{"title":"[ClinicalTrials.gov","source":"NCT07100080]","date":"","url":"https://clinicaltrials.gov/study/NCT07100080"},{"title":"[ClinicalTrials.gov","source":"NCT07431281]","date":"","url":"https://clinicaltrials.gov/study/NCT07431281"},{"title":"[ClinicalTrials.gov","source":"NCT03298451]","date":"","url":"https://clinicaltrials.gov/study/NCT03298451"},{"title":"查證截止：2026-08-03。","source":"","date":"","url":""}],"images":[{"alt":"阿斯特捷利康與 BMS 合計市值接近 4,000 億美元，但公開資訊仍只支持曾探討結合","url":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-01.png"},{"alt":"阿斯特捷利康與 BMS 坐上同一張桌的成長與專利懸崖邏輯","url":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-02.png"},{"alt":"阿斯特捷利康與 BMS 在實體瘤、免疫治療、血液腫瘤與 CAR-T 的互補及重疊","url":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-03.png"},{"alt":"阿斯特捷利康與 BMS 的合併傳聞仍須跨過交易、治理、反壟斷與管線整合四道關","url":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-04）。超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！。https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-04-astrazeneca-bms-400b-merger-talks-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}